Summit Trail Advisors LLC Grows Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Summit Trail Advisors LLC grew its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 21.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,036 shares of the medical equipment provider's stock after acquiring an additional 1,434 shares during the period. Summit Trail Advisors LLC's holdings in Intuitive Surgical were worth $3,980,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. AlphaCore Capital LLC increased its position in shares of Intuitive Surgical by 4.2% in the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after purchasing an additional 18 shares during the last quarter. Accredited Investors Inc. lifted its position in Intuitive Surgical by 1.9% during the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock valued at $543,000 after purchasing an additional 19 shares during the last quarter. Second Line Capital LLC lifted its position in Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after purchasing an additional 19 shares during the last quarter. Colonial Trust Co SC grew its stake in Intuitive Surgical by 8.8% in the 4th quarter. Colonial Trust Co SC now owns 246 shares of the medical equipment provider's stock worth $128,000 after buying an additional 20 shares in the last quarter. Finally, Crown Wealth Group LLC increased its holdings in shares of Intuitive Surgical by 4.8% in the 1st quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock worth $218,000 after buying an additional 20 shares during the last quarter. Institutional investors own 83.64% of the company's stock.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Gary Loeb sold 1,700 shares of the business's stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $513.18, for a total value of $872,406.00. Following the completion of the sale, the executive vice president directly owned 2,245 shares of the company's stock, valued at $1,152,089.10. The trade was a 43.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the transaction, the senior vice president directly owned 907 shares in the company, valued at approximately $510,740.77. This trade represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,998 shares of company stock valued at $2,611,577 in the last three months. 0.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Citigroup reaffirmed a "buy" rating and set a $650.00 price objective (up from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. Evercore ISI lowered their price target on Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating on the stock in a research report on Wednesday, April 23rd. Truist Financial cut their price objective on Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Royal Bank Of Canada decreased their price objective on Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft lowered Intuitive Surgical from a "hold" rating to a "sell" rating and cut their target price for the stock from $515.00 to $440.00 in a research note on Monday, June 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $588.95.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock traded up $3.14 during trading hours on Friday, reaching $543.74. The company's stock had a trading volume of 704,815 shares, compared to its average volume of 1,670,474. The firm has a 50 day moving average price of $537.11 and a 200-day moving average price of $536.76. The stock has a market cap of $194.89 billion, a P/E ratio of 79.73, a P/E/G ratio of 5.78 and a beta of 1.64. Intuitive Surgical, Inc. has a one year low of $413.82 and a one year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. The company had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same period last year, the company earned $1.50 earnings per share. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.